China’s largest fermentation manufacturers, long focused on pharmaceuticals and vitamins, are beginning to redirect their production capacity toward mycoprotein, yeast proteins, and precision-fermented fats. The report, written by Australian biotech and geopolitics researcher Dr. Dirk van der Kley, examines how China’s fermentation ecosystem could reshape the economics of alternative protein production. Decades of investment in fermentation-based pharmaceuticals and vitamins have left the country with extensive production capacity, technical expertise, established supply chains, and low operating costs. Why pharma manufacturers are pivotingChinese fermentation companies have historically paid little attention to food applications, since pharmaceuticals are produced in smaller volumes and sell at far higher prices. Companies with idle fermentation capacity are now looking at novel foods, particularly where the end product can command a premium.